Thermo Fisher Scientific to support BioNTech vaccine production
Thermo Fisher Scientific has signed a multiyear agreement with German immunotherapy company BioNTech, focused on supplying critical raw materials for the manufacturing of precise immunotherapy vaccine candidates.
Under the agreement, Thermo Fisher will supply nucleotides, enzymes and other critical raw materials to support BioNTech’s mRNA manufacturing platform. The four-year, non-exclusive licensing and supply agreement gives BioNTech rights to use Thermo Fisher’s technologies as part of its clinical and commercial manufacturing processes.
“Our portfolio of molecular biology products is now enabling development and commercialisation of multiple individualised therapies and other advanced medicines, and we continue to expand our capabilities to meet increasing demand,” said Gianluca Pettiti, President, Biosciences, Thermo Fisher Scientific. “We share BioNTech’s commitment to deliver life-saving therapies to patients faster, and we look forward to supporting them through clinical trials and post-approval production.”
“The relationship with Thermo Fisher Scientific secures our access to customised material essential for the manufacturing and commercialisation of our RNA-based product candidates,” said Ugur Sahin, MD, co-founder and CEO of BioNTech. “In addition, as a life science services leader, Thermo Fisher can also deliver reagents at the scale needed to expand our manufacturing capacities.”
A seasoned executive, Foster brings more than 25 years of experience in the healthcare industry.
CUREator supports and accelerates the development of Australian biotech innovations, and has...
While the majority of Australians support the use of animals in research, this support is highly...